CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig

Microbes Infect. 2005 Jun;7(7-8):1040-8. doi: 10.1016/j.micinf.2005.03.030.

Abstract

The synthetic immunomodulator cytotoxic T lymphocyte antigen 4-Ig (CTLA-4-Ig) initiates effects in human monocyte-derived dendritic cells (DC) that rely on immunosuppressive tryptophan catabolism. However, it is unable to induce suppressive properties in DC matured by CD40 engagement. Thus, CD40-driven events may physiologically set human DC free from restraint by regulatory cells expressing surface CTLA-4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abatacept
  • Animals
  • CD40 Antigens / physiology*
  • Cell Proliferation
  • Dendritic Cells / drug effects*
  • Dendritic Cells / physiology*
  • Female
  • Humans
  • Immune Tolerance / drug effects*
  • Immunoconjugates / pharmacology*
  • Interferon-gamma / physiology
  • Mice
  • Mice, Inbred DBA
  • Protein Binding
  • Tryptophan / metabolism
  • Tryptophan Oxygenase / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • CD40 Antigens
  • Immunoconjugates
  • Abatacept
  • Interferon-gamma
  • Tryptophan
  • Tryptophan Oxygenase
  • p38 Mitogen-Activated Protein Kinases